The women's health market is expanding steadily with the increasing awareness in different regions across the globe. The most common ailments that are thriving in the women's health scenario are related to the reproductive and urinary system. The overall health market is dependent on the factors such as the percentage of the younger and older women, demographic and social factors and public outlook towards contraception and family planning. The companies in the market are looking forward to expand their horizon in the untapped markets through the adoption of organic and inorganic activities such as partnerships, mergers and acquisition, and product launches. Companies are also filing for patents and approvals to the concerned authorities to stay ahead in the competition.
Agile Therapeutics, Inc., one of the market leaders, announced in its press release in October 2017, the presentation of additional results from the Phase 3 SECURE trial of its investigational low-dose combination hormonal contraceptive patch, Twirla® (AG200-15). According to Dr. Nelson, MD, Professor and Chair of Obstetrics and Gynecology at the College of Osteopathic Medicine of the Pacific, "The use of electronic diaries to collect daily bleeding data during the SECURE trial has yielded a robust package of data on the bleeding profile of Twirla. These new analyses provide information that will be very helpful to providers to guide counseling of patients considering the use of the Twirla patch, if approved."
Another market player, Allergen, also announced the inclusion of its three oral presentations and a poster being presented at the American Society for Reproductive Medicine's 73rd Annual Congress (ASRM 2017). It will present the analyses from its VENUS II trial for ulipristal acetate, an investigational drug for the treatment of abnormal uterine bleeding in women with uterine fibroids. Besides the development of new drugs, the market players are engaging in business expansion through partnerships and mergers and acquisition. In October 2017, Roivant Sciences announced a development partnership with AstraZeneca for a deprioritized investigational drug in an undisclosed indication. The drug will be developed by Roivant in a new therapeutic area that is outside of AstraZeneca's primary therapy areas.
Acknowledging the potential that this market exhibits, BIS Research has compiled a market intelligence report titled 'Global Women’s Health Market, Analysis and Forecast (2017-2023)’. According to the analyst, “The global women’s health market was estimated at $30.88 billion in 2016 and is estimated to grow over $42.12 billion by 2023. The rising geriatric population among women leading to a higher incidence rate of menopause and related diseases is the major factor driving the growth of the market.”
.jpg)
